Article

4 questions with Joanna Ng

AI_technology_innovation

Discussing an evaluation of the Rayyan artificial intelligence tool for systematic literature review screening.

AI_technology_innovation
At ISPOR US, Cencora team members presented research posters on a variety of topics across the managed care space. We took the opportunity to chat with them about their work and its potential impact. Here, Joanna Ng, Manager, Market Access Commercialization, answers questions about her poster.
AI_technology_innovation
What has inspired this research?

My poster presentation evaluates the Rayyan artificial intelligence (AI) tool for systematic literature review screening.

AI is a growing topic of interest within healthcare and various areas of healthcare are seeking to integrate it at different ways, from patient care to data aggregation.

At Cencora, we frequently conduct systematic literature reviews, a process that demands significant time and effort. Typically, sorting through the vast amount of literature in the title/abstract screening phase requires many hours. We aimed to explore ways to streamline the title/abstract screening phase with the assistance of the Rayyan AI tool.

 

Was there a hypothesis that was confirmed through the research?

Our objective was to evaluate whether the AI tool could effectively identify relevant literature in the title/abstract screening phase. Researchers face the challenge of reading and assessing each piece of literature within a heavy volume of search results for relevance to their topic; therefore, we sought to evaluate the performance and efficiencies of the Rayyan AI tool in the systematic literature review title/abstract screening phase. Across various topics, including clinical, humanistic, and economic fields, the tool performed exceptionally well in selecting the relevant articles of interest. This consistency reassured us of its reliability.

 

What is the key takeaway from your research?

We trained the Rayyan AI tool on 20% of the references for two systematic literature reviews that were previously conducted by human reviewers. The tool then predicted the relevance of the remaining references on a scale of 1-5, ranging from “most likely to exclude” to “most likely to include.” We compared its ratings with those of human reviewers and found that the tool’s sensitivity ranged from 79% to 100% across all outcomes. Specificity ranged from 8% to 62% across all outcomes. The research confirmed that the Rayyan AI tool has a high sensitivity, effectively identifying relevant articles. However, it has low to moderate specificity, meaning it struggles to exclude irrelevant articles.

There is potential for time savings with using Rayyan AI tool. Time savings ranged from 6%-47% for a single reviewer using the Rayyan AI tool. However, time savings for dual screening which is the typical standard for SLRs, with 1 human reviewer and Rayyan AI tool, were modest (3%-23%).

 

What’s next for this research?

While Rayyan AI tool provides moderate time savings and high sensitivity, we are exploring ways to increase time savings and specificity. Additionally, we are considering how to further integrate AI tools into the broader systematic literature review process. My evaluation focused on abstract and title screening, but there may be other stages of the systematic literature review process where AI tools could be beneficial.


To learn more about Joanna’s research, view her poster here.
 

Citations relevant to the content described herein are provided in the article linked here. Readers should review all available information related to the topics mentioned herein and rely on their own experience and expertise in making decisions related thereto.

 

Related resources

Article

Insights from Pharma 2025: Ready or not? Preparing for the EU HTA wave

Webinar

How full pharmacovigilance outsourcing increases efficiency and accuracy

Article

Cencora ThinkLive Cell and Gene Therapy Virtual Summit 2025

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.